메뉴 건너뛰기
소속 기관 / 학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
고객센터 ENG
주제분류

논문 기본 정보

저자정보
출처
Springer Science and Business Media LLC Future Journal of Pharmaceutical Sciences 11(1)
오류 신고하기
표지

검색

    초록·키워드

    Abstract Background Bedaquiline fumarate (BDQ) is an anti-tubercular Biopharmaceutics Classification System (BCS class-II) drug & it has very less solubility. Therefore, an effort has been made to prepare the bedaquiline fumarate co-crystal to improve its physicochemical and pharmaceutical characteristics. Results Using the solvent evaporation method, the drug bedaquiline fumarate and co-former ascorbic acid (AA) were co-crystallized. A series of analytical techniques, i.e., X-ray diffraction (XRD), Fourier transformation infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), and UV spectroscopy, etc., were used for the analysis of co-crystal to predict co-crystal formation by molecular docking. Micromeritic study and tablet formulation were done of bedaquiline fumarate and co-crystal formulation (1:2) batch. A permeability study was conducted on the chicken ileum. Conclusion Active pharmaceutical ingredients can co-crystallize with other small molecules or co-formers to create new solid dosage forms that have better physicochemical characteristics than pure drugs. 22 co-formers were screened with the drug, ascorbic acid was selected as a co-former because it has a binding energy of − 1.2 kcal/mol, two hydrogen bonds are formed, and it becomes readily soluble in water. This study indicated that ascorbic acid as a co-former can increase the dissolution profile of bedaquiline fumarate by the co-crystallization approach.

    본문·목차

    최근 본 자료 전체보기